Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Total revenues	$ 0	$ 0
Research and development expenses	6,018	6,512
Selling, general and administrative expenses	6,405	6,749
Total operating expenses	12,389	18,981
Total operating expenses	(12,389)	(18,981)
Other income (expense):
Warrant revaluation income	921	4,920
Derivative revaluation income (expense)	1,662	(1,407)
Interest expense	(771)	(828)
Other income, net	300	56
Loss before income taxes	(10,277)	(16,240)
Income taxes	0	0
Net loss	(10,277)	(16,240)
Dividend paid in-kind to preferred stockholders	(336)	(264)
Deemed dividend on preferred stock (see Note 8)	(513)	(4,099)
Net loss attributable to common stockholders	$ (11,126)	$ (20,603)
Net loss
Basic (in dollars per share)	$ (1.45)	$ (6.66)
Diluted (in dollars per share)	$ (1.45)	$ (6.67)
Weighted average number of common shares outstanding
Basic (in shares)	7,693,191	3,092,543
Diluted (in shares)	7,693,191	3,093,727
Affiliated Entity
Research and development expenses	$ (34)	$ 5,720